Phase 2Completed
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa (AMPECT)
A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-sirolimus) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)
- Sponsor
- Aadi Bioscience, Inc. (Industry)
- Enrolment
- 34 enrolled
- Conditions
- Malignant PEComa
- Interventions
- nab-Sirolimus
- Ages
- adults, older adults
- Registry
- NCT02494570
Full record on ClinicalTrials.gov
From the registry
A phase 2 multi-center investigation of efficacy of nab-sirolimus (formerly known as ABI-009 or nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa).
Primary outcomes
- Objective Overall Response Rate (ORR)
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered